Fluidiconic Biotechnology Co., Ltd.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
Fluidiconic Biotechnology develops tumor microenvironment chips and culture analysis platforms to support faster and more accurate anticancer drug development. Its TMoC series simulates molecular gradients from blood vessels to the tumor core, preserving tumor genetics and drug responses. Combined with the MedSelect platform and BioVision software, the system enables high-throughput dynamic culture, automated imaging, and visualized analysis, while the BioLab platform provides customized chip integration and ODM services for R&D teams.
Founded Year
2025
Unified Business No.
28115622
Status
Active
Number of Employees
10
Total Paid-in
Capital
41,753,334 (NT$)
Location of Company
Taiwan
, Hsinchu City
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Fluidiconic Biotechnology (NTHU spin-off) develops MedSelect™, a tumor-on-a-chip and automated drug-screening platform. Leveraging patented microfluidics and patient-derived samples, it shortens preclinical oncology cycles, reduces animal studies, and builds a transcriptomic database to power AI-assisted drug design — targeting global CRO and pharma partnerships.
